Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships University of British Columbia (UBC): license to EpiSelect computational algorithm for misfolded-protein modeling
Indications
Alzheimer's disease(Phase 1)
Catalysts
— None
Status note Lead product candidate; antibody selectively targeting toxic misfolded oligomers of amyloid-beta (non-plaque binder). Phase 1b PRECISE-AD trial in Alzheimer's disease; FDA Fast Track designation.
PMN267
Preclinical · ActiveModality: monoclonal antibody
Target misfolded TDP-43
Partnerships Collaboration with a partner with expertise in vectorization for intracellular delivery
Indications
Amyotrophic lateral sclerosis (ALS)(Preclinical)
Status note Second lead product candidate, targeting TDP-43-associated ALS (misfolded TDP-43).
PMN442
Preclinical · ActiveModality: monoclonal antibody
Target misfolded alpha-synuclein
Indications
Dementia with Lewy bodies (DLB)(Preclinical)
Parkinson's disease(Preclinical)
Multiple system atrophy (MSA)(Preclinical)
Status note Selected lead candidate for synucleinopathies (DLB, PD, MSA), selectively targeting pathogenic forms of alpha-synuclein.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.